Chimera Research Group

previous arrow
next arrow

Perimeter, OTIS – Optical Coherence Tomography and the Future of AI in Surgical Breast Cancer Treatment

Perimeter Medical Imaging AI (PINK.v) is a Toronto-based company with U.S. headquarters in Dallas, Texas developing advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during cancer excision surgery. Perimeter has an innovative FDA 510(k) approved medical device, soon to launch commercially, that is ready to disrupt breast cancer surgery […]

October 30 Biotech Update

I said that a kick was possible for the sector and it could be pulling one off.  Yesterday ended up better than I expected and was the start of that save but the market remains in a precarious position with anxiety over the election potentially overwhelming everything today.  Of course, the consensus seems to be […]

October 29th Biotech Update

As awful as the day was yesterday, the sector is not quite broken.  This is not to say that things look great but a reversal and green close today could save it.  Another day lower and we can call the trend as it would be a potentially lower low establishing.  I am not very optimistic […]

October 28th Biotech Update

Not a great start to the week (or continuation of the week) as the market and sector continue to struggle.  Given all of the potential news makers in the next couple weeks it is difficult to completely attribute the move solely to one factor.  My mantra has been that the trend is your friend and […]

Mailing List



Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press


Log In

JoinLost Password?